[
    [
        {
            "time": "",
            "original_text": "太平洋维持华兰生物买入评级：新冠疫苗获批临床，流感疫苗开启放量",
            "features": {
                "keywords": [
                    "华兰生物",
                    "新冠疫苗",
                    "获批临床",
                    "流感疫苗",
                    "放量"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "太平洋维持华兰生物买入评级：新冠疫苗获批临床，流感疫苗开启放量",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "华兰生物（002007）：腺病毒载体新冠疫苗获批临床，有望贡献业绩增量",
            "features": {
                "keywords": [
                    "华兰生物",
                    "腺病毒载体",
                    "新冠疫苗",
                    "获批临床",
                    "业绩增量"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "华兰生物（002007）：腺病毒载体新冠疫苗获批临床，有望贡献业绩增量",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "38股获券商买入评级，一心堂目标涨幅达71.22%",
            "features": {
                "keywords": [
                    "券商",
                    "买入评级",
                    "一心堂",
                    "目标涨幅"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药零售"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "38股获券商买入评级，一心堂目标涨幅达71.22%",
                "Correlation": 3,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 2,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        }
    ]
]